Functional relationship between ATAD1 and CISD1 in mitophagy regulation
Exploring the link between ATAD1 and CISD1 in mitophagy, focusing on their roles in the PINK1/Parkin pathway and USP30's regulatory influence, with potential to impact Parkinson's disease treatment strategies.
Overview
This research investigates the functional relationship between ATAD1 and CISD1 and their involvement in mitophagy, a critical cellular process for maintaining mitochondrial health. The study focuses on the role of these proteins within the PINK1/Parkin pathway, particularly how ubiquitylation of CISD1 by Parkin and deubiquitylation by USP30 influence mitophagy. Understanding these interactions is pivotal for advancing therapeutic strategies for diseases like Parkinson's, where mitochondrial dysfunction is a core issue.
Technical specifications
- Key proteins: ATAD1, a Parkin substrate involved in protein extraction under stress conditions, and CISD1, a substrate of both Parkin and USP30.
- Hypotheses: ATAD1 may assist in the clearance of PINK1 and influence the mitophagy trigger threshold through CISD1 ubiquitylation.
- Methods: Utilizing isogenic cell lines with fluorescent mitophagy reporters and employing techniques like siRNA depletion, over-expression, and CRISPRi stables in differentiated iPSCs to study synthetic effects on mitophagy.
- Applications: Potential therapeutic insights for Parkinson's disease and other conditions where mitophagy regulation is disrupted.
Technology readiness level
Currently at TRL 2, this research is in the experimental stage, leveraging mitochondrial biology expertise and established cellular models to explore protein interactions and their regulatory effects on mitophagy.
About Entact Bio
Entact Bio is a preclinical biotechnology company focused on developing precision medicines that enhance the function of beneficial proteins to address diseases with high unmet medical need. The company utilizes its proprietary end-to-end Encompass platform to design enhancement-targeting chimeric (ENTAC) molecules. These orally available, bifunctional small molecules function as molecular matchmakers, specifically recruiting enzymes known as deubiquitylases (DUBs) to target proteins. By harnessing this natural cellular mechanism to selectively remove or shorten ubiquitin chains, ENTACs can restore protein levels, relocate proteins within the cell, or alter their activity. This approach enables the targeting of previously undruggable pathways, offering a novel therapeutic modality for genetic disorders and complex diseases.
By focusing on enhancing proteins rather than inhibiting or eliminating them, Entact Bio aims to provide new treatment options for patients underserved by current therapies. Founded in 2020 and headquartered in Watertown, Massachusetts, the company is backed by a syndicate of life sciences investors and is led by an experienced management and scientific team. Their efforts are directed toward advancing a pipeline of ENTAC candidates, leveraging a deep integration of biological, chemical, and computational tools to identify targets and optimize target-DUB pairs. The company continues to mature its platform and clinical development capabilities to translate this scientific innovation into impactful medicines for human health.
Inquire about this partnering listing
Industry applications
delivered to your inbox.